Abstract Award Recipients
| Abstracts for Oral Presentation – Presidential Award | ||
|---|---|---|
| O-001 (129) | Ming-Lung Yu (Kaohsiung) |
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-world Effectiveness and Safety from a Nationwide Registry in Taiwan |
| O-004 (195) | Tai-Chung Tseng (Taipei) |
Hepatitis B Core-related Antigen Stratifies the Risk of Liver Cancer in HBeAg-negative Patients with Indeterminate Phase |
| Abstracts for Oral Presentation – Best Oral Award | ||
|---|---|---|
| O-002 (187) | Wen-Juei Jeng (Taoyuan) |
Serum Soluble Program Cell Death-1 is Predictive of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients |
| O-008 (158) | Pei-Chang Lee (Taipei) |
Declined Biosynthetic Functions of Gut Microbiota Associate with Decreased Serum Amino Acids in Cirrhotic Patients with Sarcopenia |
| O-003 (231) | Chiao-Ling Li (Taipei) |
New Classification of HBV-related HCC by Distinct Genetic Mutations |
| Abstracts for Oral Presentation – Outstanding Presentation Award | ||
|---|---|---|
| O-005 (186) | Wen-Juei Jeng (Taoyuan) |
Serum Soluble Programmed Death-1 Levels Predict the Spontaneous HBeAg Seroclearance in Chronic Hepatitis B |
| O-006 (113) | Te-Sheng Chang (Chiayi) |
Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-endemic Area: A Community-based Prospective Longitudinal Study |
| O-007 (132) | Sheng-Hung Chen (Taichung) |
Combined Liver Stiffness and Α-fetoprotein further beyond the Sustained Virologic Response Visit as Predictors of Long-term Liver-related Events in Patients with Chronic Hepatitis C |
| O-009 (227) | Kuo-Chin Chang (Kaohsiung) |
HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Related Liver Cirrhosis Patient Long-term Effect of Antiviral Treatment |
| O-010 (105) | I-Cheng Lee (Taipei) |
Determinants of Survival after Sorafenib-regorafenib Sequencing for Unresectable Hepatocellular Carcinoma |
| Abstracts for Oral Presentation – Young Investigator Award | ||
|---|---|---|
| YIA-002 (168) | Shang-Chin Huang (Taipei) |
Concurrent Metabolic Dysfunction-associated Fatty Liver Disease Reduces the Risk of Hepatocellular Carcinoma in Patients with Untreated Chronic Hepatitis B |
| YIA-003 (213) | Te-Wei Tseng (Taoyuan) |
Re-classification of Tumor Associated Neutrophils Based on the Maturation Stages is Highly Correlated with Suppression Function and Metabolic Profile in a Murine Hepatoma Model |
| YIA-004 (222) | Chi-Jung Wu (Taipei) |
Efficacy of Systemic Treatment for Unresectable Hepatocellular Carcinoma Associated with Non-viral Hepatitis Etiology |
| Abstracts for Oral Presentation – Outstanding Presentation Award | ||
|---|---|---|
| YIA-001 (153) | Yen-Chun Liu (Taoyuan) |
Different Viral Kinetics in Cirrhotic and Non-cirrhotic HBeAg Negative Chronic Hepatitis B Patients Lead to Different Off-therapy Relapse Probability and Severity |
| YIA-005 (223) | Chun-Ming Hong (Taipei) |
Combination of Post-DAA Liver Fibrosis and Neutrophil-to-lymphocyte Ratio Predicts the Development of Liver-associated Complications in Chronic Hepatitis C Patients Who Achieve Sustained Virologic Response |
| YIA-006 (62) | Hung-Yao Lin (Taipei) |
Long-term Evolution of Estimated Glomerular Filtration Rate in Patients with Antiviral Treatment for Hepatitis C Virus Infection |
| Abstracts for Best Poster Award | ||
|---|---|---|
| BP-001 (230) | Hung-Chih Yang (Taipei) |
Association of Chemokine CCL5 Immune Subtypes with Clinical Outcomes of Liver Cancer |
| BP-002 (126) | Kuei-Min Chung (Miaoli) |
CA10 is Associated with HBV-related Hepatocarcinogenesis |
| Abstracts for Outstanding Abstract Award | ||
|---|---|---|
| BP-003 (110) | Kuo-Wei Huang (Taipei) |
Durable Objective Response to Sorafenib and Role of Sequential Treatment in Unresectable Hepatocellular Carcinoma |
| BP-004 (189) | Wen-Juei Jeng (Taoyuan) |
Hepatocellular Carcinoma Incidence is Significantly Reduced in Cirrhotic Chronic Hepatitis B Patients with HBsAg Seroclearance than those with Viral Suppression |
| BP-005 (225) | Chun-Chih Chiu (Taipei) |
Bridging the Gap between High-level Trial Evidence and Real-world Experience of Systemic Therapy for Advanced Hepatocellular Carcinoma (HCC): Exploring Factors Compromising Treatment Efficacy |
| BP-006 (56) | Ming-Ying Lu (Kaohsiung) |
Decision Tree Algorithm Predicts Hepatocellular Carcinoma among Chronic Hepatitis C Patients Following Viral Eradication |
| BP-007 (61) | Pei-Chien Tsai (Kaohsiung) |
Metformin Use Greatly Reduced the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Diabetic Chronic Hepatitis C Patients: a Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) |
| BP-008 (125) | Kuo-Cheng Wu (Macao) |
Distinct Predictors of Local and Distant Recurrence in Patients with HBV-related Hepatocellular Carcinoma Receiving Radiofrequency Ablation |
| BP-009 (130) | Hung-Wei Wang (Taichung) |
Risk Stratification of Hepatocellular Carcinoma Incidence by FIB-4-based Prediction Model in Patients with Chronic Hepatitis C Receiving Anti-viral Therapy: A Nationwide Real-world Taiwanese Cohort (T-COACH) |
| BP-010 (155) | Hsin-Yun Wu (Taipei) |
Coronavirus Disease 2019-Vaccine Induced Hepatitis in a Hepatitis B Virus-endemic Area |
| BP-011 (169) | Shih-Chieh Chien (Tainan) |
Enhanced Small Heterodimer Partner (SHP) Nuclear Localization is Associated with Bile Acid Accumulation and Hepatitis in NASH Patients |
| BP-012 (210) | Takayuki Abe (Kobe) |
HCV Infection Disrupts ANX5-mediated Occludin Integrity through the Downregulation of PKC𝜂 Expression to Promote Viral Infection |
| Top 100 Outstanding Abstract (Outstanding Abstract Award) | ||
|---|---|---|
| 01. HBV-HCC: Basic and Clinical | ||
| P-001 (73) | Chih-Wen Lin (Kaohsiung) |
Heavy Alcohol Intake with ALDH2 Polymorphism Increases Hepatocellular Carcinoma and Mortality in Hepatitis B Virus-related Cirrhosis |
| P-002 (162) | Yi-Hsiang Huang (Taipei) |
Incidence of Recurrence for Early Stage Hepatocellular Carcinoma with Low HBV Viral Load Undergoing Tenofovir Alafenamide after Curative Treatment: Risk Factor and Genomic Analysis |
| P-003 (167) | Shang-Chin Huang (Taipei) |
Pre-operative Gamma-glutamyl Transferase Levels Predict Outcomes in Hepatitis B-related Hepatocellular Carcinoma after Curative Resection |
| P-004 (30) | Yung-Tsung Li (Taipei) |
Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally through Novel RNA Binding Function |
| P-005 (154) | Jui-Hsiang Chung (Yunlin) |
Different HBsAg Kinetic between Treated and Untreated HBV/HCV Co-infected Patients with Low HBV Viral Load |
| P-006 (229) | Lin Deng (Kobe) |
Oxidative Stress Sensor Keap1 Recognizes HBx Protein to Activate Nrf2/ARE Signaling Pathway, thereby Inhibiting Hepatitis B Virus Replication |
| P-007 (242) | Ya-Hui Huang (Taoyuan) |
Reduction of ACE2 Serum Concentrations by Telbivudine in Chronic Hepatitis B Patients |
| P-008 (107) | Chien-Hung Chen (Kaohsiung) |
Comparison of Incidences of Hepatocellular Carcinoma and Mortality between Patients Who Continued and Discontinued Entecavir or Tenofovir Treatment in Chronic Hepatitis B Patients without Cirrhosis |
| P-009 (120) | I-Cheng Shih (Tainan) |
The Clinical and Histologic Features of Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase |
| P-010 (145) | Chih-Chien Yao (Kaohsiung) |
Changes in Gut Microbiota of Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogs |
| P-011 (184) | Meng-Ju Lin (Taipei) |
Diversity and Composition of Gut Microbiota between Healthy Individuals and Patients with Different Stages of HBV-related Liver Diseases |
| P-012 (211) | Peter Yawe (Jos) |
A Prevalence Study of Hepatitis B and C in Lamingo, an Underserved Rural Community in Jos Nigeria |
| P-013 (178) | Cheng-Er Hsu (Taoyuan) |
Hepatitis B Virus Core-related Antigen has no Role in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Who Achieved HBsAg Seroclearance |
| P-014 (131) | Hung-Wei Wang (Taichung) |
Stratification of Hepatocellular Carcinoma Risk through the Combination of FIB-4 and ALBI-based Prediction Model in Compensated Cirrhotic Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue Therapy |
| P-015 (221) | Ta-Wei Liu (Kaohsiung) |
The Compound Annual Growth Rate of the Fibrosis-4 Index in Chronic Hepatitis B Patients |
| 02. HCV-HCC: Basic and Clinical | ||
|---|---|---|
| P-016 (54) | Wei-Fan Hsu (Taichung) |
Posttreatment Nonalcoholic Fatty Liver Disease Fibrosis Scores for Predicting Liver-related Complications in Patients with Chronic Hepatitis C Receiving Direct-acting Antiviral Agents |
| P-017 (63) | Jia-Kuo Chen (Taipei) |
Hepatitis C Virus Reinfection in Patients on Haemodialysis after Achieving Sustained Virologic Response with Antiviral Treatment |
| P-018 (127) | Ming-Lung Yu (Kaohsiung) |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-acting Antivirals |
| P-019 (128) | Ching-Chu Lo (Chiayi) |
Ledipasvir/Sofosbuvir for HCV Genotype 1, 2, 4-6 Infection: Real-world Evidence from a Nationwide Registry in Taiwan |
| P-020 (179) | Yen-Chun Liu (Taoyuan) |
Distinct Hepatocellular Carcinoma Risks in Treated Chronic Hepatitis C Patients with Different Definitions of Advanced Chronic Liver Disease |
| P-021 (192) | Kuo-Cheng Wu (Macao) |
Direct-acting Antivirals Reduce the Risk of Distant Recurrence and Improve Survival of HCV-related Hepatocellular Carcinoma after Radiofrequency Ablation |
| P-022 (226) | Shu-Chi Wang (Kaohsiung) |
Systematic Integration of Persistent HCV Infection Related Liver Hepatocellular Carcinoma miRNA-mRNA Regulation |
| P-023 (166) | Chih-Hsuan Luan (Taipei) |
Residual Risk of Hepatocellular Carcinoma Development for Chronic Hepatitis C Patients Treated by All-oral Direct-acting Antivirals with Sustained Virological Response |
| P-024 (136) | Chao-Hung Hung (Kaohsiung) |
Effectiveness and Safety of 8-week Glecaprevir/Pibrentasvir in HCV Treatment Naïve Patients with Compensated Cirrhosis: Real-world Experience from Taiwan HCV Registry |
| P-025 (140) | Jing-Houng Wang (Kaohsiung) |
Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-by-village Screening and Linking to Outreach Hepatology Care |
| P-026 (118) | Kao-Chi Chang (Chiayi) |
Changes in Renal Function in Patients with Chronic Hepatitis C Treated with Sofosbuvir-velpatasvir |
| 03. Non-viral HCC, NASH/MAFLD HCC: Basic and Clinical | ||
|---|---|---|
| P-027 (94) | Chon Kit Pun (Taipei) |
Acute Reduction of Environmental Temperature Induced Transient Portal Pressure Surge via α-receptor-mediated Pathway in Cirrhotic or Portal Hypertensive Rats |
| P-028 (183) | Yi-Cheng Chen (Taoyuan) |
Higher Grade of Hepatic Steatosis is Associated with Higher Recurrence Free Survival after Hepatocellular Carcinoma Resection in Patients with Nonalcoholic Fatty Liver Disease |
| P-029 (228) | Feng-Pai Tsai (Taipei) |
Impact of Concurrent Metabolic Associated Fatty Liver Disease on Outcomes of Early Stage Hepatocellular Carcinoma Receiving Radiofrequency Ablation |
| P-030 (106) | Kuo-Hsuan Huang (Kaohsiung) |
Metabolic Risks are Increasing in Non-B Non-C Early-stage Hepatocellular Carcinoma: A 10-year Follow-up Study |
| P-031 (205) | Bou-Zenn Lin (Taipei) |
Differences of Clinical Features between Nonalcoholic Fatty Liver Disease and Hepatitis C Virus-related Hepatocellular Carcinoma |
| P-032 (214) | Jee-Fu Huang (Kaohsiung) |
Lean with Metabolic Abnormalities Carry a High Risk for Advanced Fibrosis in Taiwanese Metabolic Dysfunction-associated Fatty Liver Disease Patients- a Community-based Observation |
| P-033 (224) | Yu-Shun Chiu (Taipei) |
Impact of Concurrent Metabolic Associated Fatty Liver Disease on Outcomes of Hepatocellular Carcinoma Receiving Surgical Resection |
| 04. HCC Genomic and Molecular Pathogenesis | ||
|---|---|---|
| P-034 (170) | Kuang-Tsu Yang (Kaohsiung) |
FGF4 Expression in Patients with Hepatocellular Carcinoma with Immune Microenvironment Compared with FN1 |
| 05. HCC Epidemiology, Prevention, and Diagnosis | ||
|---|---|---|
| P-035 (191) | Ming-Chao Tsai (Kaohsiung) |
Comparison of Portal and Capsular Microscopic Vascular Invasion in the Outcomes of Early HCC after Curative Resection |
| P-036 (58) | Mo-Fan Chen (Taipei) |
Comparison between Dynamic CT and Gadoxetic Acid-enhanced MRI with the Liver Imaging Reporting and Data System to Assess HCC before Liver Resection |
| P-037 (84) | Shu-Hsien Lin (Kaohsiung) |
Reappraisal of the Roles of Alpha-fetoprotein in Hepatocellular Carcinoma Surveillance Using Large-scale Nationwide Database and Hospital-based Information |
| P-038 (176) | Yi-Cheng Lu (Taipei) |
High Prothrombin Induced by Vitamin K Absence or Antagonist-II Level Predicts 1-year Risk of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B |
| P-039 (161) | Chung-Feng Huang (Kaohsiung) |
The Clinical Utility of Elecsys GAAD Score in the Diagnosis of Hepatocellular Carcinoma |
| 06. HCC Treatment | ||
|---|---|---|
| P-040 (27) | Chih-Horng Wu (Taipei) |
Computed Tomography–Defined Sarcopenia in Patients with Hepatocellular Carcinoma Undergoing Radioembolisation: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles |
| P-041 (82) | Hui-Chi Liu (Taipei) |
Comparison of Dosimetry Models to Predict Outcome for Radioembolization in Patients with Unresectable Hepatocellular Carcinoma: A Single-center Experience |
| P-042 (218) | Chi-Jung Wu (Taipei) |
Viral Etiology Determines Outcomes of Immunotherapy in Unresectable Hepatocellular Carcinoma: A Real-world Study |
| P-043 (220) | Chi-Jung Wu (Taipei) |
Programmed Death–Ligand 1 Expression Level Associates with Response to Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma |
| P-044 (134) | Wei Teng (Taoyuan) |
Combination of CRAFITY Score with Alpha-fetoprotein Response Predicts a Favorable Outcome of Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma |
| P-045 (123) | Chao-Wei Lee (Taoyuan) |
Laparoscopic Liver Resection is Associated with Less Significant Muscle Loss than the Conventional Open Approach |
| P-046 (157) | Yung-Hsuan Yang (Taipei) |
Tumor Burden Assessments as Prognostic Factors in HCC Patients Receiving Yttrium-90 Radioembolization |
| P-047 (175) | Yu-Ting Kao (Taoyuan) |
Combining Locoregional Therapy Provides Better Survival in Hepatocellular Carcinoma Patients Receiving 2nd Line Systemic Regimen |
| P-048 (177) | Ya-Wen Hung (Taipei) |
Radiological Features and Outcomes in Patients with Intermediate Stage Hepatocellular Carcinoma Undergoing Consecutive Transcatheter Arterial Chemoembolization |
| P-049 (185) | Chian-Tzu Huang (Taipei) |
Transarterial Chemoembolization has Worse Survival than Surgical Resection in Intermediate Stage Hepatocellular Carcinoma with Intermediate and High Tumor Burden |
| P-050 (219) | Chi-Jung Wu (Taipei) |
Lenvatinib plus Pembrolizumab for Systemic Therapy-naïve and -experienced Unresectable Hepatocellular Carcinoma |
| P-051 (59) | Ching-Sheng Hsu (Chiayi) |
Nivolumab plus Sorafenib versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Real-world Propensity Score-matched Study |
| P-052 (97) | Chia-Chi Wang (Taipei) |
The Predictors of Liver Dysfunction Using Modified ALBi Grade for Hepatocellular Carcinoma Patients after Transhepatic Arterial Chemo-embolization |
| P-053 (121) | Wei-Fan Hsu (Taichung) |
Concurrent Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Therapy Yields Better Outcome than Immune Checkpoint Inhibitor Monotherapy in Patients with Advanced Hepatocellular Carcinoma |
| P-054 (116) | Yuan-Hung Kuo (Kaohsiung) |
Impact of Hepatitis Etiologies on Lenvatinib as First-line Therapies for Unresectable Hepatocellular Carcinoma. |
| P-055 (159) | Chia-Wei Lin (Taipei) |
3D Imaging of Cleared Tissues and Intravital Microscopy Reveal Vascular Changes and T-cell Dynamics in Tumor Micro-environments |
| P-056 (209) | Po-Yao Hsu (Kaohsiung) |
Artificial Intelligence Based on Serum Biomarkers Predicts the Efficacy of Lenvatinib for Unresectable Hepatocellular Carcinoma |
| P-057 (88) | Ming-Jeng Kuo (Tainan) |
Predictive Factor Analysis for Early-stage Hepatocellular Carcinoma after Primary Curative Treatment–Comparing Surgical with Matched Nonsurgical Methods |
| P-058 (137) | Hung-Chih Chiu (Taipei) |
Real-world Experience of Lenvatinib for Advanced Hepatocellular Carcinoma |
| P-059 (235) | Shih-Jer Hsu (Taipei) |
Real-world Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma |
| P-060 (181) | Chien-Wei Peng (Taoyuan) |
Distinct Predictors of Early and Late HCC Recurrence in Patients with Complete Response after TACE |
| P-061 (60) | Shao-Wu Lee (Taichung) |
A Real-world Single-center Experience of Combined Tyrosine Kinase Inhibitor and Immunotherapy Therapy as the 1st-line Treatment for Patients with Advanced Hepatocellular Carcinoma |
| P-062 (70) | Geeng-Jia Hu (Taipei) |
Prediction of HCC Recurrence after RFA by Assessing the Ablative Margin. |
| P-063 (147) | Wei-Lun Tsai (Kaohsiung) |
Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma Non-responsive to Transarterial Embolization |
| P-064 (150) | Yuan-Hung Kuo (Kaohsiung) |
Comparison of Sorafenib Use in Hepatitis B Virus or Hepatitis C Virus-related Hepatocellular Carcinoma |
| P-065 (197) | Chern-Horng Lee (Taoyuan) |
Daily Aspirin Reduced the Incidence of Hepatocellular Carcinoma and Overall Mortality in Patients with Cirrhosis |
| P-066 (203) | Shih-Chieh Chien (Tainan) |
The Impacts of Ablation Strategies and Parameters on the Outcome of HCC Treated by Radio-frequency Ablation – A Single Center, Prospective Study. |
| P-067 (204) | Po-Chih Yang (Taipei) |
Dynamic Indocyanine Green Fluorescence Imaging Identified Right Hepatic Vein Drainage Area for Precise Resection of Hepatocellular Carcinoma with Hepatic Vein Invasion |
| 07. Cholangiocarcinoma | ||
|---|---|---|
| P-068 (57) | Chen-Ta Chi (Taipei) |
Outcome Predictors of Gemcitabine-based or Fluoropyrimidine-based Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma |
| P-069 (104) | Yu-Min Lin (Taipei) |
Metachronous Intrahepatic Cholangiocarcinoma after Treatment of Hepatocellular Carcinoma and Vice Versa |
| P-070 (232) | Yu-Min Lin (Taipei) |
Different Incidence Trends of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Taiwan—Analysis of National Liver Cancer Registry Data for the 2010–2019 Period |
| 08. Artifical Intelligence for HCC (Prognostic or Risk Score) | ||
|---|---|---|
| P-071 (198) | Rifaldy Fajar (Yogyakarta) |
Machine Learning Classification of Liver Cancer Based on Computerized Tomography Scan Image Using Probabilistic Neural Network Model Algorithm |
| P-072 (85) | Md Azharuddin (New Delhi) |
Artificial Intelligence for Diagnosis of Hepatocellular Carcinoma: Evidence-based Systematic Review |
| P-073 (156) | Jia-I Liao (Taipei) |
Tumor Burden Score as a New Prognostic Marker for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization |
| P-074 (188) | Wei-Fan Hsu (Taichung) |
Modified Cutoffs for ALBI Grade for Patients with Early, Intermediate, or Advanced Hepatocellular Carcinoma |
| 09. Others | ||
|---|---|---|
| P-075 (194) | Eslam Habba (Tanta) |
Occult Hepatitis C after Direct Acting Antiviral, a Study in a Cohort of Egyptian Patients with Thrombocytopenia |
| P-076 (216) | Hao-Che Chang (Taipei) |
High Aspartate Aminotransferase Level s Predictive of Disease Progression of Coronavirus Disease 2019 |
| P-077 (67) | Chih-Lin Lin (Taipei) |
The Impact of Body Mass Index on Clinicopathological Features of Nonalcoholic Fatty Liver Disease in Taiwan |
| P-078 (71) | Teng-Yu Lee (Taichung) |
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype-1b Hepatitis C Virus Infection |
| P-079 (95) | Ying-Ying Yang (Taipei) |
Low Lymphocyte-to-monocyte Ratio, Calcitriol, and CD206 Predict Occurrence of Acute on Chronic Liver Failure in Patients with Cirrhosis |
| P-080 (133) | Yung-Yu Hsieh (Chiayi) |
Direct-acting Antivirals Ameliorate the De Novo Development of Esophageal Varices in Patients with Hepatitis C Related Liver Cirrhosis |
| P-081 (141) | Ming-Tsung Lin (Kaohsiung) |
Comparison of Serum WFA+-M2BP, FIB-4, and APRI for Cirrhosis and Esophageal Varices Prediction in Hepatoma Patients |
| P-082 (148) | Hui-Chun Huang (Taipei) |
Microbiota Transplants from Feces or Gut Content Attenuated Portal Hypertension and Portosystemic Collaterals in Cirrhotic Rats |
| P-083 (239) | Szu-Jen Wang (Kaohsiung) |
The Role of 5-methoxytryptophan in Liver Fibrosis of NAFLD/NASH Animal Model |
| P-084 (234) | Jee-Fu Huang (Kaohsiung) |
Cardiovascular Risk Assessment by Non-invasive Methods in Hemodialysis Patients after Hepatitis C Virus Eradication by Direct-acting Antiviral Agents |
| P-085 (72) | Hui-Fen Chen (Taipei) |
The Differences in Clinical Manifestations between Patients having Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) with versus without Chronic Hepatitis B Infection-A multi-center Study |
| P-086 (98) | Yen-Chun Chen (Chiayi) |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-acting Antivirals |
| P-087 (108) | Chien-Hung Chen (Kaohsiung) |
The Long-term Incidences and Predictors of HBsAg Loss after Entecavir or Tenofovir Cessation in HBeAg-negative Chronic Hepatitis B Patients without Cirrhosis Who did not Receive Retreatment |
| P-088 (138) | Hsueh-Chien Chiang (Taipei) |
Comparison of Body Weight and Lipid Profiles Following Tenofovir Disoproxil Fumarate or Entecavir Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients – An Interim Analysis |
| P-089 (174) | Si-Hsuan Chen (Taipei) |
A Mouse Model of Liver Metastatic Colorectal Cancer |
| P-090 (215) | Chia-Yen Dai (Kaohsiung) |
Cryoglobulinemia after Antiviral Treatment and Liver Fibrosis in Chronic Hepatitis C Patients |
| P-091 (238) | Yu-Ju Wei (Kaohsiung) |
The Benefits of HCV Eradication among Uremic Patients on Maintenance Hemodialysis |
| P-092 (193) | Chien-Lin Chen (Hualien) |
Effects of Exercise and Diet Modification on Controlled Attenuated Parameter Values in Obese Patients with Metabolic Associated Fatty Liver Disease |
| P-093 (200) | Altangerel Enkhjargal (Ulaanbaatar) |
Qualitative Analysis of the Patient Journey: HDV Management in Rural and Urban Settings of Mongolia |
| P-094 (47) | Kuo-Chih Tseng (Chiayi) |
The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation Following Direct-acting Antiviral Therapy in HBV/HCV Coinfected Patients |
| P-095 (102) | Chi-Ming Tai (Kaohsiung) |
HBV Reactivation after Bariatric Surgery for HBV-infected Obese Patients |
| P-096 (212) | Kwong-Ming Kee (Kaohsiung) |
Community-based Screening by Anti-HCV Reflex HCV Ag Test and Accessible Post-screening Care toward Elimination of Hepatitis C in Two Hyperendemic Townships |
| P-097 (237) | Yu-Ju Wei (Kaohsiung) |
HCV Eradication Improved Quality of Life in Uremia Patients under Maintenance Hemodialysis |
| P-098 (240) | Yu-Ju Wei (Kaohsiung) |
The Sustainability of Sustained Virologic Respons (SVR) in Uremia Patients under Maintenance Hemodialysis after HCV Eradication |
| P-099 (114) | Te-Sheng Chang (Chiayi) |
Effectiveness of Glecaprevir/Pibrentasvir for Patients with Hepatitis C and Compensated Cirrhosis in a Real-world Setting in Taiwan |
| P-100 (64) | Yi-Wen Huang (Taipei) |
Ropeginterferon Alfa-2b Every Two Weeks is an Effective and Safe Treatment Option for Genotype 2 Chronic Hepatitis C |
| P-101 (101) | Yi-Wen Huang (Taipei) |
Comparison and Correlation of Fibrosis Stage Assessment by Collagen Proportionate Area (CPA) and Noninvasive Fibrosis Indices in Patients with Chronic Hepatitis B: A Pilot Study |
| P-102 (142) | Hung-Wei Wang (Taichung) |
Programming of Maternal High Fat with Microplastics Exposure in Offspring Fatty Liver |
| P-103 (164) | Shiu-Feng Huang (Taipei) |
Introduction of Taiwan Liver Cancer Network |
